Table 3. Frequency of mutation by molecule in naive and ART pre-treated patients with virological failure.
Patients Category | Patients | HIV-1 RNA VL (Log/mL) | NRTI | NNRTIs | ||||||||
ZDV | D4T | 3TC/FTC | ABC | DDI | TDF | NVP | EFV | ETR | RVP | |||
ARV-naïve patients | 10-1806 | 3,7 | R | R | R | PR | PR | PR | R | R | SS | N/A |
10-1701 | 4,5 | R | R | R | PR | PR | PR | R | R | PR | N/A | |
10-1866 | 3,4 | PR | R | R | PR | PR | PR | R | R | PR | R | |
10.1828 | 4,3 | PR | R | R | PR | PR | PR | R | R | SS | R | |
11.2005 | 3,7 | PR | PR | R | PR | PR | PR | R | R | PR | PR | |
11.1919 | 4,8 | PR | PR | R | PR | PR | PR | R | R | PR | PR | |
10.1872 | 4,4 | PR | PR | R | PR | PR | PR | R | R | PR | N/A | |
ARV pre-exposed patients | 12.2095 | 5,8 | R | R | R | R | R | R | R | R | PR | R |
10-1779 | 4,6 | R | R | R | R | R | R | R | R | PR | N/A | |
10-1885 | 5,5 | PR | R | R | PR | PR | PR | R | R | R | N/A | |
10-1896 | 4,4 | R | R | R | SS | R | SS | R | R | PR | N/A | |
10-1830 | 5,4 | R | R | R | PR | PR | PR | R | R | R | N/A | |
10-1796 | 4,8 | R | R | R | R | R | SS | R | R | SS | N/A | |
10-1754 | 5,6 | R | R | R | SS | PR | SS | R | R | PR | N/A | |
1759 | 4,1 | R | R | R | SS | R | SS | PR | PR | R | N/A | |
11.1990 | 5,5 | PR | PR | R | R | R | PR | R | R | PR | PR | |
10-1836 | 5 | PR | PR | PR | PR | PR | PR | SS | PR | PR | N/A | |
1991 | 4,2 | PR | PR | PR | PR | PR | PR | PR | PR | PR | N/A | |
10-1900 | 3,5 | PR | PR | PR | PR | PR | PR | PR | PR | PR | N/A | |
11-1963 | 6,4 | PR | PR | PR | PR | PR | PR | PR | PR | PR | N/A | |
10-1876 | 3,4 | PR | PR | R | PR | PR | PR | R | R | R | N/A | |
2002 | 4,1 | R | R | R | PR | SS | SS | R | R | R | PR |
R = Resistant, PR = Possible resistant, SS = sensitive.